ArticlePloS one2012
Creatine protects against excitoxicity in an in vitro model of neurodegeneration.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Single-Dose Creatine Reduces Sleep Deprivation-Induced Deterioration in Cognitive Performance.Nutrients · 2026Trial
- The beneficial properties of CBDA in diet-induced neuroinflammation.Inflammopharmacology · 2026Article
- Unsupervised Clustering of ACC and Hippocampal Metabolites Identifies Subgroups in Antipsychotic-Naïve First-Episode Psychosis.Schizophrenia bulletin · 2026Article
- Fourier Transform Infrared Imaging Supported by Raman Spectroscopy Reveals Biochemical Changes in Adult Rat Brains Following Prenatal Exposure to a Ketogenic Diet.ACS chemical neuroscience · 2026Article
- Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes followingFrontiers in stroke · 2026Article
- Creatine-weighted imaging in patients with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.Antioxidants (Basel, Switzerland) · 2025Article
- Creatine supplementation and muscle-brain axis: a new possible mechanism?Frontiers in nutrition · 2025Review
- Intranasal delivery of dodecyl creatine ester alleviates motor deficits and increases dopamine levels in a 6-OHDA rat model of parkinsonism.Frontiers in aging neuroscience · 2025Article
- "Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and Function.Sports medicine (Auckland, N.Z.) · 2023Review
- Creatine Activity as a Neuromodulator in the Central Nervous System.Archives of Razi Institute · 2023Review
- Decision tree distinguish affective disorder diagnosis from psychotic disorder diagnosis with clinical and lab factors.Heliyon · 2022Article
- A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.Schizophrenia research · 2022Article
- Review
- The role of nutrients in human neurodevelopment and their potential to prevent neurodevelopmental adversity.Frontiers in nutrition · 2022Review
- Review
- Metabolomic Responses to Manganese Dose in SH-SY5Y Human Neuroblastoma Cells.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- Potential for use of creatine supplementation following mild traumatic brain injury.Concussion (London, England) · 2017Review
- In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7.Movement disorders : official journal of the Movement Disorder Society · 2015Article
- Diminution of Oxidative Damage to Human Erythrocytes and Lymphocytes by Creatine: Possible Role of Creatine in Blood.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Creatine has been shown to be neuroprotective in aging, neurodegenerative conditions and brain injury. As a common molecular background, oxidative stress and disturbed cellular energy homeostasis are key aspects in these conditions. Moreover, in a recent report we could demonstrate a life-enhancing and health-promoting potential of creatine in rodents, mainly due to its neuroprotective action. In order to investigate the underlying pharmacology mediating these mainly neuroprotective properties of creatine, cultured primary embryonal hippocampal and cortical cells were challenged with glutamate or H(2)O(2). In good agreement with our in vivo data, creatine mediated a direct effect on the bioenergetic balance, leading to an enhanced cellular energy charge, thereby acting as a neuroprotectant. Moreover, creatine effectively antagonized the H(2)O(2)-induced ATP depletion and the excitotoxic response towards glutamate, while not directly acting as an antioxidant. Additionally, creatine mediated a direct inhibitory action on the NMDA receptor-mediated calcium response, which initiates the excitotoxic cascade. Even excessive concentrations of creatine had no neurotoxic effects, so that high-dose creatine supplementation as a health-promoting agent in specific pathological situations or as a primary prophylactic compound in risk populations seems feasible. In conclusion, we were able to demonstrate that the protective potential of creatine was primarily mediated by its impact on cellular energy metabolism and NMDA receptor function, along with reduced glutamate spillover, oxidative stress and subsequent excitotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.